RA-BEAM

March 3, 2017March 3, 2017

Olumiant Improved RA Symptoms Better Than Humira, Study Finds

Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to placebo and a current standard treatment, Humira (adalimumab). These findings were published in The New England ... Read more

February 17, 2017February 17, 2017

RA Patients Treated with Olumiant Show Improvements Compared to Humira, Placebo

News, rheumatoid arthritis

In a pivotal Phase 3 clinical trial, Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to Humira (adalimumab) and placebo, according to a ... Read more

October 23, 2015October 26, 2015

Baricitinib Demonstrated Superior Activity in Patients with Rheumatoid Arthritis

News

Lilly and Incyte recently announced results from their fourth Phase III study (RA-BEAM) on baricitinib in patients with active rheumatoid arthritis (RA). Historically, these clinical trials passed through several stages, which started as first ... Read more